PCM
CLBT icon

Prelude Capital Management’s Cellebrite CLBT Stock Holding History

Prelude Capital Management’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,829
Closed -$205K – 1174
2025
Q2 		$205K Buy
+12,829
New +$229K 0.02% 807
2023
Q1 		– Sell
-20,349
Closed -$88.7K – 1219
2022
Q4 		$88.7K Buy
+20,349
New +$90.9K ﹤0.01% 1091
2022
Q1 		– Sell
-26,075
Closed -$209K – 1876
2021
Q4 		$209K Buy
+26,075
New +$246K 0.01% 1545

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return

Prelude Capital Management's CLBT Position: Q3 2025 in Review

Prelude Capital Management sold out of Cellebrite (CLBT) in Q3 2025, closing a stake of 12,829 shares — an estimated $205K sold.

Prelude Capital Management first reported a position in CLBT in Q4 2021 and held it in 3 quarters. The position peaked at $209K in Q4 2021. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2025.

  • Prelude Capital Management reported no remaining Cellebrite position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 12,829 Cellebrite shares in Q3 2025, an estimated $205K.
  • Prelude Capital Management first reported a position in Cellebrite in Q4 2021 and held it in 3 quarters.
  • Prelude Capital Management's Cellebrite position peaked at $209K in Q4 2021.
  • 197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.